To reimburse or not to reimburse? Calculating the cost-effectiveness of multiple indications of Pembrolizumab in The Netherlands

Additional Metadata
Keywords	cost-effectiveness;pembrolizumab;The Netherlands
Thesis Advisor	Uyl-de Groot, C.A.
Persistent URL	hdl.handle.net/2105/62551
Series	Health Economics (ESHPM)
Organisation	Erasmus School of Health Policy & Management
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Verbeek, F.A.J. (2022, June). To reimburse or not to reimburse? Calculating the cost-effectiveness of multiple indications of Pembrolizumab in The Netherlands. Health Economics (ESHPM). Retrieved from http://hdl.handle.net/2105/62551

Publication